Capital Investment Advisors LLC Sells 2,533 Shares of Solventum Co. (NYSE:SOLV)

Capital Investment Advisors LLC trimmed its stake in Solventum Co. (NYSE:SOLV) by 25.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,414 shares of the company’s stock after selling 2,533 shares during the period. Capital Investment Advisors LLC’s holdings in Solventum were worth $490,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in SOLV. Czech National Bank grew its holdings in Solventum by 6.5% in the 4th quarter. Czech National Bank now owns 29,966 shares of the company’s stock valued at $1,980,000 after buying an additional 1,820 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in Solventum by 24.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after buying an additional 9,333 shares during the last quarter. Nordea Investment Management AB grew its holdings in Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after buying an additional 431,986 shares during the last quarter. Everence Capital Management Inc. acquired a new stake in Solventum in the 4th quarter valued at approximately $305,000. Finally, Modus Advisors LLC acquired a new stake in Solventum in the 4th quarter valued at approximately $25,000.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Mizuho assumed coverage on Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 target price on the stock. Piper Sandler lifted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating on the stock. Morgan Stanley lifted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Solventum currently has an average rating of “Hold” and a consensus price target of $68.29.

Solventum Price Performance

Shares of NYSE SOLV opened at $72.00 on Thursday. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The business has a fifty day moving average of $69.18 and a two-hundred day moving average of $65.24.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.